BioPharmSignal logoBioPharmSignal

Biotech News

BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026

BioNTech (BNTX)BioNTechEarnings

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2026 on Tuesday, November 3, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.

Related news

REPLReplimune Group2026-10-22 12:00 EST

Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026

RVMDRevolution Medicines2026-10-21 20:05 EST

Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026

IMVTImmunovant2026-10-21 11:00 EST

Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

NRIXNurix Therapeutics2026-10-12 20:05 EST

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

GERNGeron2026-10-21 12:00 EST

Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026

ARGXArgenx2026-10-15 05:00 EST

argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026

REGNRegeneron Pharmaceuticals2026-09-24 20:05 EST

Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026

TEVATeva Pharmaceutical Industries2026-09-23 20:45 EST

Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET

EXELExelixis2026-10-15 20:05 EST

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

ANABAnaptysBio, Inc.2026-09-21 20:15 EST

Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update

View all latest news

BioNTech

Next-Generation Biopharmaceutical Platform BioNTech develops medicines for cancer and other serious diseases using complementary immunotherapy and vaccine technologies. Its current oncology strategy integrates checkpoint and angiogenesis modulation, antibody-drug conjugates and mRNA cancer immunotherapies across multiple tumor...

Recent company news

BNTXBioNTech2026-10-22 10:45 EST

BioNTech treibt klinische Phase-3-Studie zu Pumitamig mit Gileads gegen TROP2-gerichtetem Antikörper-Wirkstoff-Konjugat Sacituzumab Govitecan bei Dreifach-Negativem Brustkrebs voran

BNTXBioNTech2026-10-22 10:45 EST

BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer

BNTXBioNTech2026-10-20 10:45 EST

BioNTech veröffentlicht am 3. November 2026 Ergebnisse für das dritte Quartal 2026 und informiert über operativen Fortschritt

BNTXBioNTech2026-10-20 10:45 EST

BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026

BNTXBioNTech2026-10-19 10:45 EST

BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026

Stock data

Close
91.29 USD
Market cap
22.54B USD
Exchange
NASDAQ
Sector
Nucleic Acid Drugs
Location
United States